Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
Status:
Active, not recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate
the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)